Abstract 175P
Background
Cancer cells evade the human immune system by manipulating the tumor-immune microenvironment (TIME) via suppressing the immuno-activator and promoting the immune-suppressive mediators. Hence, targeting immuno-modulatory factors became an ingenious treatment option, particularly for cancer types that shows scarcity of treatment options such as triple negative breast cancer (TNBC). Novel immuno-modulatory targets such as Galectin (GAL) 3 and 9 have been found to be overexpressed in TNBC, repressing the immune surveillance. Similarly, TNBC tumors were found to prevent the activation of immune infiltrating lymphocytes via overexpressing immune checkpoint CD155 expression on its surface. MHC class I polypeptide–related sequence A (MICA) and MICB are stress-induced ligands essential for innate immunity activation at the TIME. However, their expression is also often suppressed in TNBC, leading to immune suppression and poor prognosis. Our research group has extensively worked on microRNAs to modulate multiple targets simultaneously. Hence, this work unravels the expression profile of the miR-548c in BC tissues, evaluate its unprecedented immunomodulatory role in TNBC via altering GAL3/9, CD155, and MICA/B expression.
Methods
BC female patients (n=20) were recruited. In-silico analysis was used to identify miRNAs that target immunomodulatory targets. MDA-MB-231 TNBC cells were cultured and transfected by oligonucleotides. Total RNA was extracted using Biazol, reverse transcribed and quantified using qRT-PCR.
Results
miRNA-548c is a down-regulated tumor suppressor miRNA in BC tissues compared to its normal counterparts. MiRNA-548c was validated to regulate the immunogenic profile in TNBC. Given the overexpression of the immuno-suppressive GAL3, GAL9, and CD155, miR-548c simultaneously constrained their expression in TNBC cells. Moreover, ectopic expression of miR-548c in MDA-MB-231 cells resulted in a marked upregulation of the expression of the immuno-activators MICA and MICB, enhancing the overall immunogenic profile of TNBC cells.
Conclusions
This study identifies miRNA-548c as a booster of the immune surveillance by concomitant adjustment for the immunogenic ligands expressed/produced by the TNBC cell.
Legal entity responsible for the study
The authors.
Funding
This work was supported by Swiss National Science Foundation (SNSF), grant IZSTZ0_198887.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
190P - Immune-related roles of B7H3 in glioblastoma
Presenter: Arnaud Simonet
Session: Poster Display
191P - Senolytic treatment remodels glioblastoma microenvironment
Presenter: Alexa Saliou
Session: Poster Display
192P - Analysis of Tumor-Associated Macrophages and Tumor-infiltrating Lymphocytes within the Tumor Microenvironment of Primary Tumors and Matched Brain Metastases
Presenter: Markus Kleinberger
Session: Poster Display
193P - Engagement of sialylated glycans with Siglec receptors on suppressive myeloid cells inhibit anti-cancer immunity via CCL2
Presenter: Ronja Wieboldt
Session: Poster Display
194P - Achieving Reproducible Maturation Staging of Tertiary Lymphoid Structures: from Imaging Mass Cytometry Data to Pathology Applications
Presenter: Marion Le Rochais
Session: Poster Display
195P - IMMUcan - Toward a better understanding of the tumor microenvironment to inform precision oncology approaches.
Presenter: Marie Morfouace
Session: Poster Display
196P - Local glycan engineering induces systemic antitumor immune reactions via antigen cross-presentation
Presenter: Natalia Rodrigues Mantuano
Session: Poster Display
197P - Computational pathology pipeline enables quantification of intratumor heterogeneity and tumor-infiltrating lymphocyte score
Presenter: Daniel Tiezzi
Session: Poster Display
198P - Polarization of tumor-associated macrophages enhanced by 2-HP-_-cyclodextrin modified PLGA nanoparticles
Presenter: HAO YUAN
Session: Poster Display
199P - Scalable multiplexed image analysis across cancer types as part of the IMMUcan consortium
Presenter: Nils Eling
Session: Poster Display